Edition:
United Kingdom

People: Esperion Therapeutics Inc (ESPR.OQ)

ESPR.OQ on NASDAQ Stock Exchange Global Market

52.33USD
24 May 2019
Change (% chg)

$1.38 (+2.71%)
Prev Close
$50.95
Open
$51.37
Day's High
$52.43
Day's Low
$50.96
Volume
72,620
Avg. Vol
200,459
52-wk High
$60.98
52-wk Low
$35.86

McGovern, Mark 

Dr. Mark E. McGovern, M.D., FACC, FACP is an Independent Director of Esperion Therapeutics Inc. He is a board-certified cardiologist with over 20 years of experience developing lipid regulating therapies, and since 2007, has served as a consultant to the pharmaceutical industry in cardiovascular and lipid regulation. Dr. McGovern spent 10 years, from 1997 to 2007, at Kos Pharmaceuticals, where he last served as Executive Vice President, Medical Affairs, and Chief Medical Officer, prior to its acquisition by Abbott Laboratories. Prior to joining Kos Pharmaceuticals, Dr. McGovern spent 11 years at Bristol-Myers Squibb (NYSE: BMY), from 1986 to 1997, in various capacities, including Executive Director, Heart Failure and Atherosclerosis Clinical Research. Dr. McGovern earned his Bachelor's degree summa cum laude from Princeton University and his medical degree from the University of Vermont. Dr. McGovern is a Fellow of the American College of Cardiology and the American College of Physicians, and has published extensively on lipid management and its role in the treatment of coronary heart disease. We believe that Dr. McGovern is qualified to serve as a member of our Board based on his broad experience in the industry in which we operate and his expertise in lipid regulating therapies.

Basic Compensation

Total Annual Compensation, USD --
Restricted Stock Award, USD 343,846
Long-Term Incentive Plans, USD --
All Other, USD 38,500
Fiscal Year Total, USD 382,346

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --